Compositions and methods for treating degenerative, age-related and trauma-induced disorders
AssigneeS.I.S. Shulov Innovative Science Ltd.
InventorNaftali Primor
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing degenerative, age-related and trauma-induced disorders, particularly of the eye, are provided.
Claims20
A method of treating a degenerative, age-related, or trauma-induced disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a peptide of Formula I:
- pGlu-X1-X2-X3-OH, wherein:
- X1 is selected from the group consisting of Asn and Thr;
- X2 is selected from the group consisting of Trp, Phe and Tyr;
- and
- X3 is selected from the group consisting of Lys, Lys attached through its amino side chain to a C4-C30 alkyl group, and Thr;
- or a salt or derivative thereof, and a pharmaceutically acceptable carrier,
- wherein the degenerative, age-related, or trauma-induced disease or disorder is a neurodegenerative disease or disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS) or a degenerative, age-related, or trauma-induced eye disease or disorder selected from the group consisting of glaucoma, Fuchs' corneal dystrophy, cataract or trauma induced following cataract surgery, corneal erosion, and age-related macular degeneration.
A method of treating a degenerative, age-related, or trauma-induced eye disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a peptide of Formula I:
- pGlu-X1-X2-X3-OH, wherein:
- X1 is selected from the group consisting of Asn and Thr;
- X2 is selected from the group consisting of Trp, Phe and Tyr;
- and
- X3 is selected from the group consisting of Lys, Lys attached through its amino side chain to a C4-C30 alkyl group, and Thr;
- or a salt or derivative thereof, and a pharmaceutically acceptable carrier.
A method of treating a disease associated with ROS-related oxidative stress in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a peptide of Formula I:
- pGlu-X1-X2-X3-OH, wherein:
- X1 is selected from the group consisting of Asn and Thr;
- X2 is selected from the group consisting of Trp, Phe and Tyr;
- and
- X3 is selected from the group consisting of Lys, Lys attached through its amino side chain to a C4-C30 alkyl group, and Thr;
- or a salt or derivative thereof, and a pharmaceutically acceptable carrier,
- wherein the disease associated with ROS-related oxidative stress is a neurodegenerative disease or disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS);
- or a disease selected from the group consisting of glaucoma, Fuchs' corneal dystrophy, cataract or trauma induced following cataract surgery, corneal erosion, and age-related macular degeneration.
Dependencies are inferred from the claim text.